We used 2 commercially available antibody tests to estimate seroprevalence of severe acute respiratory syndrome coronavirus 2 infection in Japan during June 2020. Of 7,950 samples, 8 were positive by both assays. Using 2 reliable antibody tests in conjunction is an effective method for estimating seroprevalence in low prevalence settings.
All Keywords
【저자키워드】 COVID-19, 2019 novel coronavirus disease, coronavirus disease, severe acute respiratory syndrome coronavirus 2, viruses, respiratory infections, zoonoses, immunology, antibodies, SARS-CoV-2, coronavirus, serology, Seroprevalence, diagnostics, Antibody responses, Japan, 【초록키워드】 Infection, Prevalence, Antibody test, acute respiratory syndrome, positive, effective, assays,
【저자키워드】 COVID-19, 2019 novel coronavirus disease, coronavirus disease, severe acute respiratory syndrome coronavirus 2, viruses, respiratory infections, zoonoses, immunology, antibodies, SARS-CoV-2, coronavirus, serology, Seroprevalence, diagnostics, Antibody responses, Japan, 【초록키워드】 Infection, Prevalence, Antibody test, acute respiratory syndrome, positive, effective, assays,
우리는 2020년 6월 동안 일본에서 중증 급성 호흡기 증후군 코로나바이러스 2 감염의 혈청 유병률을 추정하기 위해 2개의 상업적으로 이용 가능한 항체 테스트를 사용했습니다. 7,950개의 샘플 중 8개가 두 분석 모두에서 양성이었습니다. 2개의 신뢰할 수 있는 항체 검사를 함께 사용하는 것은 유병률이 낮은 환경에서 혈청 유병률을 추정하는 효과적인 방법입니다.